MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7

doi:10.18632/oncotarget.5224

科研成果详情

题名	MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7
作者	Cui, Ri1,4; Kim, Taewan 2; Fassan, Matteo 1,3; Meng, Wei 5; Sun, Hui-Lung 1; Jeon, Young-Jun 1; Vicentini, Caterina 6; Tili, Esmerina 1,7; Peng, Yong 8; Scarpa, Aldo 9; Liang, Guang10; Zhang, Yong Kui 11; Chakravarti, Arnab 5; Croce, Carlo M.1
发表日期	2015-09-08
发表期刊	ONCOTARGET 影响因子和分区
语种	英语
原始文献类型	Article
关键词	miR-224 lung cancer caspase-3 caspase-7
其他关键词	HEPATOCELLULAR-CARCINOMA ; PROSTATE-CANCER ; DOWN-REGULATION ; BREAST-CANCER ; UP-REGULATION ; EXPRESSION ; APOPTOSIS ; ACTIVATION ; MUTATIONS ; MECHANISM
摘要	We recently reported that miR-224 was significantly up-regulated in non-small cell lung cancer (NSCLC) tissues, in particular in resected NSCLC metastasis. We further demonstrated that miR-224 functions as an oncogene in NSCLC by directly targeting TNFAIP1 and SMAD4. However, the biological functions of miR-224 in NSCLC are controversial and underlying mechanisms of miR-224 in the progression and metastasis of lung cancer remain to be further explored. Here we report that caspase3 (CASP3) and caspase7 (CASP7) are previously unidentified targets of miR-224 in NSCLC, and that miR-224 promotes lung cancer cells proliferation and migration in part by directly targeting CASP7 and down-regulating its expression. In addition, miR-224 attenuated TNF-alpha induced apoptosis by direct targeting of CASP3 resulting in reduction of cleaved PARP1 expression in lung cancer cells. Furthermore, the expression of miR-224 negatively correlates with the expression of CASP7 and CASP3 in tissue samples from patients with lung cancer. Finally, we found that activated NF kappa B signaling is involved in the regulation of miR-224 expression in lung cancer. Our study provides new insight in understanding of oncogenic role of miR-224 in the lung cancer pathogenesis and suggests that NF-kappa B/miR-224/CASP3, 7 pathway could be a putative therapeutic target in lung cancer.
资助项目	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 CA166905, U01 CA152758]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U01CA166905, U01CA152758] Funding Source: NIH RePORTER
出版者	IMPACT JOURNALS LLC
出版地	ORCHARD PARK
ISSN	1949-2553
EISSN	1949-2553
卷号	6 期号:26 页码:21802-21815
DOI	10.18632/oncotarget.5224
页数	14
WOS类目	Oncology ; Cell Biology
WOS研究方向	Oncology ; Cell Biology
WOS记录号	WOS:000362954800021
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	26307684
PMC记录号	PMC4673127
SCOPUSEID	2-s2.0-84941241946
通讯作者地址	[Croce, Carlo M.]Department of Molecular Virology,Immunology and Medical Genetics,Comprehensive Cancer Center,The Ohio State University,Columbus,United States
Scopus学科分类	Oncology
引用统计	被引频次：63[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20185
专题	药学院（分析测试中心）其他_附属舟山医院（舟山医院）
通讯作者	Croce, Carlo M.
作者单位	1.Department of Molecular Virology,Immunology and Medical Genetics,Comprehensive Cancer Center,The Ohio State University,Columbus,United States; 2.Department of Molecular and Cellular Oncology,The University of Texas MD Anderson Cancer Center,Houston,United States; 3.Department of Medicine (DIMED),University of Padua,Padua,Italy; 4.Chemical Biology Research Center,School of Pharmaceutical Sciences,Lung Cancer Research Center,The Zhoushan Hospital of Wenzhou Medical University,Wenzhou, Zhejiang,China; 5.Department of Radiation Oncology,Comprehensive Cancer Center,The Ohio State University,Columbus,United States; 6.Applied Research on Cancer Network (ARC-NET) Research Centre,University of Verona,Verona,Italy; 7.Department of Anesthesiology,Wexner Medical Center,The Ohio State University,Columbus,United States; 8.Division of Thoracic Surgery,State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Collaborative Innovation Center of Biotherapy,Chengdu,China; 9.Department of Pathology and Diagnostics,University of Verona,Verona,Italy; 10.Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou, Zhejiang,China; 11.Department of Cardio-Thoracic Surgery,Lung Cancer Research Center,Zhoushan Hospital of Wenzhou Medical University,Zhoushan, Zhejiang,China
第一作者单位	药学院（分析测试中心）; 附属舟山医院（舟山医院）; 生物有机与药物化学研究中心
推荐引用方式 GB/T 7714	Cui, Ri,Kim, Taewan,Fassan, Matteo,et al. MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7[J]. ONCOTARGET,2015,6(26):21802-21815.
APA	Cui, Ri., Kim, Taewan., Fassan, Matteo., Meng, Wei., Sun, Hui-Lung., ... & Croce, Carlo M.. (2015). MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7. ONCOTARGET, 6(26), 21802-21815.
MLA	Cui, Ri,et al."MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7".ONCOTARGET 6.26(2015):21802-21815.